ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Pandion Therapeutics Inc

Pandion Therapeutics Inc (PAND)

60.05
0.00
(0.00%)
Closed November 05 3:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
60.05
Bid
59.70
Ask
59.90
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
60.05
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

PAND Latest News

Pandion Shares More Than Double Premarket on Takeover by Merck

By Colin Kellaher Shares of Pandion Therapeutics Inc. more than doubled in premarket trading Thursday after the clinical-stage biotechnology company agreed to be acquired by drug giant Merck &...

Merck to Buy Pandion Therapeutics for $1.85 Billion

By Colin Kellaher Merck & Co. on Thursday said it agreed to buy clinical-stage biotechnology company Pandion Therapeutics Inc. for $60 a share, or about $1.85 billion, in cash. The purchase...

Merck to Acquire Pandion Therapeutics

Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc...

Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoi...

WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...

Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...

Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expa...

-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...

Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies...

Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...

Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 202...

WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SPPLSIMPPLE Ltd
US$ 1.18
(268.75%)
401.72M
NUWENewellis Inc
US$ 2.80
(105.88%)
99.67M
ADNAdvent Technologies Holdings Inc
US$ 3.34
(75.79%)
64.32M
STAFStaffing 360 Solutions Inc
US$ 2.8301
(66.48%)
52.45M
OMICSingular Genomics Systems Inc
US$ 22.28
(65.53%)
320.33k
TOIIWOncology Institute Inc
US$ 0.0101
(-47.67%)
58.23k
SSPEW Scripps Company
US$ 2.2701
(-35.51%)
4.25M
GCTKGlucoTrack Inc
US$ 1.15
(-33.91%)
82.44k
ILLRTriller Group Inc
US$ 2.86
(-33.18%)
2.32M
FGFFundamental Global Inc
US$ 15.2501
(-31.46%)
209.53k
SPPLSIMPPLE Ltd
US$ 1.18
(268.75%)
401.72M
ELABElevai Labs Inc
US$ 0.0202
(-30.10%)
289.72M
NVDANVIDIA Corporation
US$ 136.05
(0.48%)
184.5M
SQQQProShares UltraPro Short QQQ
US$ 7.52
(1.08%)
166.26M
DJTTrump Media and Technology Group Corporation
US$ 34.34
(12.37%)
119.84M

Your Recent History

Delayed Upgrade Clock